At Biogen, we are committed to improving the lives of patients living with serious illnesses. Through relentless innovation and leading-edge manufacturing capabilities, we develop novel therapies to address high unmet medical needs. We have extended that mission to the pursuit of developing biosimilars of advanced biologics.

Biosimilars are a group of biologic medicines that are similar to currently available biologic therapies known as originators. Now that some of these medicines have reached patent expiry, regulators across the world are creating pathways to allow for similar versions — biosimilars — of originator biologics to enter the market.1, 2

It’s an opportunity to fundamentally expand access to important biologics for patients and physicians.

— Alpna Seth
Senior Vice President, Biosimilars

By 2017, the cost of biologics is expected to represent 20% of the total global expenditure on medical therapy.3 Biosimilar medicines can help reduce the total expected expenditure of these much-needed biologic therapies, thereby increasing access for patients.4 Biosimilars offer a new way to provide value within the current global health system by introducing savings that will help fund ongoing medical innovation.

Having successfully delivered complex originator biologics for more than 30 years, today Biogen is one of only a handful of companies with the leading manufacturing capabilities and the deep scientific expertise needed to produce consistently high-quality biosimilars of advanced biologics. By bridging our heritage of scientific innovation with an opportunity to reduce healthcare costs and increase access to biologics, developing biosimilars is a compelling way in which we can make a difference in the lives of the patients we serve.

Approved biosimilars

Now approved in the European Union.

Biosimilars pipeline

REFERENCES
1. European Commission, Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products, page 6
2. U.S. Food and Drug Administration, Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009, page 5
3. The Global Use of Medicines: Outlook through 2017. Report by the IMS Institute for Healthcare Infomatics, page 9
4. European Commission, Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products, page 36